Research Use Only: This product is supplied for laboratory research and in-vitro studies. Not for human or veterinary administration.
Cagrilintide (5mg) / Tirz (10mg)
Cagrilintide (5mg) / Tirz (10mg)
- Profile: Cagrilintide 5mg / Tirzepatide 10mg research blend for laboratory studies
- Applications: GLP-1 and GIP receptor pathway mechanisms
- Quality: >=95% Purity (HPLC Verified)
- Metabolic Synergy Research
- In-Vitro Receptor Profiling
- HPLC Verified (≥98% Purity)
Ships same-day if ordered before 2PM EST
Research Overview
Cagrilintide/Tirzepatide Blend is a research peptide combination designed for metabolic studies. Cagrilintide is a long-acting amylin analog that modulates appetite and glucose homeostasis, while Tirzepatide is a dual GIP/GLP-1 receptor agonist investigated for its effects on insulin secretion and body weight regulation.
This blend enables researchers to study the synergistic effects of amylin and incretin pathway modulation in preclinical metabolic models.
References:
Lau DCW et al., Lancet, 2021;398(10317):2160-2172
Jastreboff AM et al., N Engl J Med, 2022;387(3):205-216
Frias JP et al., Lancet, 2021;398(10317):2249-2260
Primary Research Applications
Mechanism of Action
This blend targets two distinct but complementary metabolic pathways:
Cagrilintide (Amylin Analog): Binds to amylin receptors (AMY1-3) in the area postrema and hypothalamus, reducing glucagon secretion, slowing gastric emptying, and promoting satiety through central appetite suppression.
Tirzepatide (GIP/GLP-1 Dual Agonist): Activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, enhancing glucose-dependent insulin secretion, suppressing glucagon release, and modulating lipid metabolism in adipose tissue.
The combination provides synergistic effects on metabolic parameters by targeting both central (hypothalamic) and peripheral (pancreatic, adipose) pathways.
“The combination provides synergistic effects on metabolic parameters by targeting both hypothalamic and peripheral pancreatic pathways.”
Preclinical Research Summary
Preclinical studies have investigated both compounds individually and in combination:
Cagrilintide Studies: In rodent models, cagrilintide demonstrated dose-dependent reductions in food intake and body weight, with effects on hepatic lipid accumulation and glucose tolerance. Long-acting formulations showed sustained receptor engagement over 7+ days.
Tirzepatide Studies: Preclinical data showed superior glycemic control compared to selective GLP-1 agonists, with significant effects on body weight and lipid profiles. In vitro studies confirmed dual receptor binding with balanced GIP/GLP-1 activity.
Combination Rationale: The complementary mechanisms suggest potential for enhanced metabolic outcomes compared to monotherapy approaches, warranting investigation in controlled research settings.